These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34398333)

  • 1. The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice.
    Harris MA; Shekhar TM; Miles MA; Cerra C; Hawkins CJ
    Clin Exp Metastasis; 2021 Oct; 38(5):441-449. PubMed ID: 34398333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
    Shekhar TM; Burvenich IJG; Harris MA; Rigopoulos A; Zanker D; Spurling A; Parker BS; Walkley CR; Scott AM; Hawkins CJ
    BMC Cancer; 2019 Sep; 19(1):924. PubMed ID: 31521127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
    Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
    J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
    Shekhar TM; Miles MA; Gupte A; Taylor S; Tascone B; Walkley CR; Hawkins CJ
    Oncotarget; 2016 Jun; 7(23):33866-86. PubMed ID: 27129149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
    Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
    Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.
    Kamata E; Kawamoto T; Ueha T; Hara H; Fukase N; Minoda M; Morishita M; Takemori T; Fujiwara S; Nishida K; Kuroda R; Kurosaka M; Akisue T
    Anticancer Res; 2017 Nov; 37(11):6097-6106. PubMed ID: 29061790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells.
    Chen KF; Lin JP; Shiau CW; Tai WT; Liu CY; Yu HC; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Aug; 84(3):268-77. PubMed ID: 22580047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OTUD7B suppresses Smac mimetic-induced lung cancer cell invasion and migration via deubiquitinating TRAF3.
    Zhang B; Yang C; Wang R; Wu J; Zhang Y; Liu D; Sun X; Li X; Ren H; Qin S
    J Exp Clin Cancer Res; 2020 Nov; 39(1):244. PubMed ID: 33198776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
    Koshkina NV; Kleinerman ES; Waidrep C; Jia SF; Worth LL; Gilbert BE; Knight V
    Clin Cancer Res; 2000 Jul; 6(7):2876-80. PubMed ID: 10914737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.
    Houghton PJ; Kang MH; Reynolds CP; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Maris JM; Billups CA; Smith MA
    Pediatr Blood Cancer; 2012 Apr; 58(4):636-9. PubMed ID: 21681929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
    Brands RC; Herbst F; Hartmann S; Seher A; Linz C; Kübler AC; Müller-Richter UDA
    Clin Oral Investig; 2016 Dec; 20(9):2325-2332. PubMed ID: 26846923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases.
    Kryeziu K; Moosavi SH; Bergsland CH; Guren MG; Eide PW; Totland MZ; Lassen K; Abildgaard A; Nesbakken A; Sveen A; Lothe RA
    J Transl Med; 2021 Sep; 19(1):384. PubMed ID: 34496878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
    Koshkina N; Yang Y; Kleinerman ES
    Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
    Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F
    Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling.
    Afsahi A; Silvestri CM; Moore AE; Graham CF; Bacchiochi K; St-Jean M; Baker CL; Korneluk RG; Beug ST; LaCasse EC; Bramson JL
    Front Immunol; 2023; 14():1179827. PubMed ID: 37138866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis.
    Fu Z; Deng B; Liao Y; Shan L; Yin F; Wang Z; Zeng H; Zuo D; Hua Y; Cai Z
    BMC Cancer; 2013 Dec; 13():580. PubMed ID: 24314238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
    Gordon N; Kleinerman ES
    J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK.
    Hu XK; Rao SS; Tan YJ; Yin H; Luo MJ; Wang ZX; Zhou JH; Hong CG; Luo ZW; Du W; Wu B; Yan ZQ; He ZH; Liu ZZ; Cao J; Wang Y; Situ WY; Liu HM; Huang J; Wang YY; Xia K; Qian YX; Zhang Y; Yue T; Liu YW; Zhang HQ; Tang SY; Chen CY; Xie H
    Theranostics; 2020; 10(17):7710-7729. PubMed ID: 32685015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
    Prasopporn S; Suppramote O; Ponvilawan B; Jamyuang C; Chanthercrob J; Chaiboonchoe A; More-Krong P; Kongsri K; Suntiparpluacha M; Chanwat R; Korphaisarn K; Okada S; Sampattavanich S; Jirawatnotai S
    Front Oncol; 2022; 12():1021632. PubMed ID: 36531039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
    Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S
    Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.